ITRM Iterum Therapeutics
- 1.9000
- -0.1000-5.00%
- 1.8900
- -0.0100-0.53%
Iterum Therapeutics News
Maxim Group Maintains Iterum Therapeutics(ITRM.US) With Buy Rating
H.C. Wainwright Maintains Iterum Therapeutics(ITRM.US) With Buy Rating, Maintains Target Price $5
Iterum Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Iterum Therapeutics, Lowers Price Target to $5
Buy Rating Justified for Iterum Therapeutics Amid Strong Sulopenem Prospects and Upcoming FDA Advisory Committee Review
H.C. Wainwright Maintains Iterum Therapeutics(ITRM.US) With Buy Rating, Cuts Target Price to $5
Iterum Therapeutics Analyst Ratings
Iterum Therapeutics Analyst Ratings
Buy Rating Affirmed for Iterum Therapeutics Amid Positive Sulopenem Prospects and Financial Stability
Analysts Are Bullish on These Healthcare Stocks: IO Biotech (IOBT), Iterum Therapeutics (ITRM)
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI), Iterum Therapeutics (ITRM) and Cara Therapeutics (CARA)
Iterum Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Iterum Therapeutics, Maintains $6 Price Target
Buy Rating Affirmed for Iterum Therapeutics on Strong Market Potential and Financial Stability
HC Wainwright & Co. : The Iterum Therapeutics (ITRM.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $6.00.
Iterum Therapeutics Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Abbott Labs (ABT), Iterum Therapeutics (ITRM)
Analysts Offer Insights on Healthcare Companies: CalciMedica (CALC), Apollomics (APLM) and Iterum Therapeutics (ITRM)
Iterum Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Iterum Therapeutics, Maintains $6 Price Target
No Data